Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers.
Pubu M AbeyasingheJeffrey D LongAdeel RaziDorian PustinaJane S PaulsenSarah J TabriziGovinda R PoudelNellie Georgiou-KaristianisPublished in: Movement disorders : official journal of the Movement Disorder Society (2021)
Monitoring volumetric changes throughout a trial (alongside primary and secondary clinical end points) may provide a more comprehensive understanding of improvements in functional outcomes and help to improve the design of clinical trials. Alternatively, our results suggest that imaging deserves consideration as an end point in clinical trials because of the prospect of greater sensitivity. © 2021 International Parkinson and Movement Disorder Society.